Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
45 studies found for:    pkd
Show Display Options
Rank Status Study
21 Completed Mesenchymal Stem Cells Transplantation in Patients With Chronic Renal Failure Due to Polycystic Kidney Disease
Conditions: Chronic Renal Failure;   Polycystic Kidney Disease
Intervention: Biological: Intravenous injection autologous mesenchymal stem cells
22 Recruiting Metformin as a Novel Therapy for Autosomal Dominant Polycystic Kidney Disease
Condition: Polycystic Kidney, Autosomal Dominant
Interventions: Drug: Metformin;   Other: Placebo
23 Recruiting Pulsed Oral Sirolimus in Autosomal Dominant Polycystic Kidney Disease
Conditions: Polycystic Kidney, Type 1 Autosomal Dominant Disease;   Polycystic Kidney, Type 2 Autosomal Dominant Disease
Interventions: Drug: Sirolimus;   Drug: Placebo
24 Completed A New Diet for Patients With Autosomal Dominant Polycystic Disease (ADPKD)
Condition: Autosomal Dominant Polycystic Kidney Disease
Intervention: Other: ADPKD Diet
25 Completed 8-Week Study of Tolvaptan Dose Forms in Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Condition: Autosomal Dominant Polycystic Kidney Disease
Interventions: Drug: Tolvaptan MR;   Drug: Tolvaptan IR;   Drug: Placebo
26 Unknown  Clinical Trial to Slow the Progression of ADPKD
Conditions: Kidney, Polycystic;   Kidney, Polycystic, Autosomal Dominant
Intervention: Drug: anti-hypertensive medications
27 Completed Sirolimus Treatment in Patients With Autosomal Dominant Polycystic Kidney Disease: Renal Efficacy and Safety
Condition: Polycystic Kidney
Interventions: Drug: Sirolimus;   Drug: conventional therapy
28 Completed Pilot Study of RNA as a Biomarker for Autosomal Dominant Polycystic Kidney Disease
Conditions: Chronic Kidney Disease;   Polycystic Kidney, Autosomal Dominant
Intervention:
29 Completed Water as Therapy in Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Condition: Autosomal Dominant Polycystic Kidney Disease
Intervention: Other: Water prescription
30 Completed Personalized Diabetic Kidney Disease Risk Info to Initiate and Maintain Health Behavior Changes
Condition: Diabetic Kidney Disease
Intervention:
31 Recruiting UAB HRFD Core Center: Core A: The Hepato/Renal Fibrocystic Diseases Translational Resource
Conditions: Hepato/Renal Fibrocystic Disease;   Autosomal Recessive Polycystic Kidney Disease;   Joubert Syndrome;   Bardet Biedl Syndrome;   Meckel-Gruber Syndrome;   Congenital Hepatic Fibrosis;   Caroli Syndrome;   Oro-Facial-Digital Syndrome Type I;   Nephronophthisis;   Glomerulocystic Kidney Disease
Intervention:
32 Completed Evaluation of Gut Bacteria in Patients With Polycystic Kidney Disease
Condition: Polycystic Kidney Disease
Intervention:
33 Completed Euglycemic Clamp Study Comparing Two New Insulin Glargine Formulations in Subjects With Type 1 Diabetes Mellitus
Condition: Type1 Diabetes
Intervention: Drug: Insulin glargine new formulation HOE901
34 Completed Effect of Alirocumab SAR236553 (REGN727) Administered on Top of Ezetimibe or Fenofibrate on Lipid Profiles in Healthy Subjects
Condition: Hypercholesterolemia
Interventions: Drug: alirocumab SAR236553 (REGN727);   Drug: ezetimibe;   Drug: ezetimibe placebo;   Drug: fenofibrate
35 Completed Evaluation of the Blood Levels of the Drug (Lixisenatide), the Plasma Glucose Levels and Safety in Paediatric and Adult Patients With Type 2 Diabetes
Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Lixisenatide (AVE0010);   Drug: Placebo
36 Completed Single Dose Study With a New Insulin Glargine Formulation and Lantus® in Japanese Patients With Type 1 Diabetes Mellitus
Condition: Type 1 Diabetes Mellitus
Interventions: Drug: Insulin glargine HOE901;   Drug: Insulin glargine - New formulation HOE901
37 Completed Study of the Tolerability, Safety, Pharmacokinetics and Pharmacodynamics of Alirocumab SAR236553 (REGN727)
Condition: Hypercholesterolemia
Intervention: Drug: alirocumab SAR236553 (REGN727)
38 Completed Injection Site Tolerability, Safety, Pharmacokinetics and Pharmacodynamics Study After a Single Dose Subcutaneous Treatment of Alirocumab SAR236553 (REGN727)
Condition: Hypercholesterolemia
Intervention: Drug: alirocumab SAR236553 (REGN727)
39 Completed Injection Site Tolerability, Safety, Pharmacokinetics, Pharmacodynamics in Different Single-Dose Treatments of Alirocumab SAR236553 (REGN727) in Healthy Subjects
Condition: Hypercholesterolemia
Intervention: Drug: alirocumab SAR236553 (REGN727)
40 Terminated Pharmacokinetics, Pharmacodynamics and Safety Evaluation of SAR279356 in Intensive Care Unit Mechanically Ventilated Patients
Condition: Infection Prophylaxis
Interventions: Drug: SAR279356;   Drug: placebo

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-45) Show next page of results    Last Page
Indicates status has not been verified in more than two years